Skip to main content

Table 1 Clinicopathological characteristics of cohorts A and triple-negative breast cancer cohort B

From: CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers

Parameter Cohort A Cohort B (TNBC)
N (%) N (%)
All patients 398 156
Age, years
  <50 124 (31.2) 72 (46.15)
  ≥50 257 (64.6) 80 (50.1)
 Unknown 17 (4.3) 4 (2.56)
Nodal status
 Positive 78 (19.6) 15 (9.6)
 Negative 203 (51.0) 39 (25)
 Unknown 117 (29.4) 104 (66.6)
Tumor size
  <2 cm 217 (54.5) 44 (28.2)
 2–5 cm 73 (17.3) 74 (47.43)
 Unknown 108 (27) 38 (24.35)
Grade
 1–2 97 (24.37) 45 (28.84)
 3 103 (25.87) 78 (50.00)
 NA/Unknown 198 (49.7) 32 (2)
ERα
 Positive (1–3) 264 (66.3)  
 Negative (0) 89 (22.3)  
 Unknown 45 (11.3)  
HER2
 Positive (3+) 20 (5)  
 Negative (0–1+) 272 (68.3)  
 Unknown/Equivocal 106 (26.6)  
Adjuvant treatment
 Hormonal only 93 (23.4)  
 Chemotherapy only 72 (18.1)  
 Hormonal+Chemo 48 (12.1)  
 None 89 (22.4)  
 Unknown 96 (24.1)  
Follow-up (m)
 Median (range) 139 (3–385) 52 (4–231)
  1. Abbreviations: ERα estrogen receptor alpha, NA not available, TNBC triple-negative breast cancer